mAbs

Article	Citations
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	273
BERT2DAb: a pre-trained model for antibody representation based on amino acid sequences and 2D-structure	178
Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb	95
Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice	70
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance	64
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	61
Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A	58
Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C H 1-C λ interfac	51
HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure	47
Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms	40
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	37
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering	36
Development of T-cell engagers selective for cells co-expressing two antigens	33
A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies	32
Engineering death resistance in CHO cells for improved perfusion culture	31
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	31
In silico prediction of post-translational modifications in therapeutic antibodies	29
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics	28
A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties	28
A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation	27
In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom	27
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats	26
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	25
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4 + T cell interl	24
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	23

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	22
Charge heterogeneity of therapeutic monoclonal antibodies by different cIEF systems: views on the current situation	21
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies	21
Antibody-mediated degradation of 4R-tau restores mitochondrial membrane polarization in human induced pluripotent stem cell-derived neurons with the MAPT 10+16 mutation	20
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	20
Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches	20
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	20
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	20
CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody	20
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer	20
Correction	19
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	19
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	19
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer	19
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity	17
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models	16
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy	16
Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody	16
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions	15
Modulation of the high concentration viscosity of IgG 1 antibodies using clinically validated Fc mutations	15
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	14
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	14
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	13
Predicting purification process fit of monoclonal antibodies using machine learning	13
Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study	13
Reproducibility and flexibility of monoclonal antibody production with Nicotiana benthamiana	13
Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies	13
Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development	13
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches	13
Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2	13
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	12
“Stapling” scFv for multispecific biotherapeutics of superior properties	12
Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy	12
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT	12
Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method	12
Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies	12
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics	11
Investigating protein–excipient interactions of a multivalent V HH therapeutic protein using NMR spectroscopy	11
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning	11
Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies	11
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants	10
Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics	10
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species	10
The Fab portion of immunoglobulin G has sites in the CL domain that interact with Fc gamma receptor IIIa	10
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	10
Harnessing the potential of machine learning for advancing “Quality by Design” in biomanufacturing	10
Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic	9
Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing	9
Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model	9
Biparatopic antibodies: therapeutic applications and prospects	8

Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate	8
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	8
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras	8
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	8
Assessing developability early in the discovery process for novel biologics	8
Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring	8
Correction	8
Improved therapeutic index of an acidic pH-selective antibody	8
Expanding the structural resolution of glycosylation microheterogeneity in therapeutic proteins by salt-free hydrophilic interaction liquid chromatography tandem mass spectrometry	7
Heavy chain-only antibodies with a stabilized human VH in transgenic chickens for therapeutic antibody discovery	7
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies	7
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1	7
Reduction of monoclonal antibody viscosity using interpretable machine learning	7
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	7
Correction	6
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques	6
Understanding the impacts of dual methionine oxidations in complementarity-determining regions on the structure of monoclonal antibodies	6
Alternative splicing for tuneable expression of protein subunits at desired ratios	6
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	6
Correction	6
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	6
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers	6
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration	6
Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry	6
Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen	6
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	6
A pivotal decade for bispecific antibodies?	6
Correction	6
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy	6
Predicting antibody binders and generating synthetic antibodies using deep learning	5
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity	5
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	5
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	5
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	5
Structural and functional characterization of a monoclonal antibody blocking TIGIT	5
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	5
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	5
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	5
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	5
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	4
Large-scale data mining of four billion human antibody variable regions reveals convergence between therapeutic and natural antibodies that constrains search space for biologics drug discovery	4
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	4
Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer	4
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	4
Ranking mAb–excipient interactions in biologics formulations by NMR spectroscopy and computational approaches	4
Exploration of the antibody–drug conjugate clinical landscape	4
Impact of IgG subclass on monoclonal antibody developability	4
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity	4
Effects of the COVID-19 pandemic: new approaches for accelerated delivery of gene to first-in-human CMC data for recombinant proteins	4
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	4
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	4
Molecular recognition requires dimerization of a VHH antibody	4
Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency	4
Accelerating the speed of innovative anti-tumor drugs to first-in-human trials incorporating key de-risk strategies	4
Antibodies to watch in 2024	4
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	4
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	4
Can antibodies be “vegan”? A guide through the maze of today’s antibody generation methods	4
Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab	4
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	4
Predictive modeling of concentration-dependent viscosity behavior of monoclonal antibody solutions using artificial neural networks	4
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	4
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	4
Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody	4
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	4
Strategies for clinical dose optimization of T cell-engaging therapies in oncology	3
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions	3
Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders	3
Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells	3
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	3
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy	3
Unique epitope–antibody interactions in the intrinsically disordered proteoglycan-like domain of human carbonic anhydrase IX defined by high-resolution NMR combined with yeast surface display	3
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	3
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	3
Blueprint for antibody biologics developability	3
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo	3
Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands	3
Determination of ultra-trace metal-protein interactions in co-formulated monoclonal antibody drug product by SEC-ICP-MS	3
Use of poxvirus display to select antibodies specific for complex membrane antigens	3
Therapeutic index improvement of antibody-drug conjugates	3

Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity	3
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors	3